(Q34409297)

English

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis (English)

1 reference

Europe PubMed Central

2 August 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

mycophenolate mofetil

1 reference

ChEBI release 2020-05-28

Bianca Weinstock-Guttman

6

object named as

Bianca Weinstock-Guttman

1 reference

Europe PubMed Central

2 August 2017

Michael G Dwyer

object named as

Michael G Dwyer

17

0 references

Benjamin M. Greenberg

object named as

Benjamin M Greenberg

19

0 references

18

object named as

Olaf Stüve

1 reference

Europe PubMed Central

2 August 2017

Robert Zivadinov

21

object named as

Robert Zivadinov

1 reference

Europe PubMed Central

2 August 2017

2

object named as

Gary Cutter

0 references

author name string

Elliot M Frohman

1

1 reference

Europe PubMed Central

2 August 2017

Gina Remington

3

1 reference

Europe PubMed Central

2 August 2017

Hongjiang Gao

4

1 reference

Europe PubMed Central

2 August 2017

Howard Rossman

5

1 reference

Europe PubMed Central

2 August 2017

Jacqueline E Durfee

7

1 reference

Europe PubMed Central

2 August 2017

Amy Conger

8

1 reference

Europe PubMed Central

2 August 2017

Ellen Carl

9

1 reference

Europe PubMed Central

2 August 2017

Katherine Treadaway

10

1 reference

Europe PubMed Central

2 August 2017

Eric Lindzen

11

1 reference

Europe PubMed Central

2 August 2017

Amber Salter

12

1 reference

Europe PubMed Central

2 August 2017

Teresa C Frohman

13

1 reference

Europe PubMed Central

2 August 2017

Anjali Shah

14

1 reference

Europe PubMed Central

2 August 2017

Angela Bates

15

1 reference

Europe PubMed Central

2 August 2017

Jennifer L Cox

16

1 reference

Europe PubMed Central

2 August 2017

Michael K Racke

20

1 reference

Europe PubMed Central

2 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2010

1 reference

Europe PubMed Central

2 August 2017

Therapeutic advances in neurological disorders

1 reference

Europe PubMed Central

2 August 2017

3

1 reference

Europe PubMed Central

2 August 2017

1

1 reference

Europe PubMed Central

2 August 2017

15-28

1 reference

Europe PubMed Central

2 August 2017

Emerging Therapies for Relapsing Multiple Sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Opportunistic infections and other risks with newer multiple sclerosis therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Functional MR imaging in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Central nervous system infections - a potential complication of systemic immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Multiple sclerosis--the plaque and its pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Mycophenolate mofetil in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

The design and development of an immunosuppressive drug, mycophenolate mofetil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Mechanisms of action of mycophenolic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

6 July 2018

Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mechanisms of Action of Mycophenolic Acid

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

MRI--the perfect surrogate marker for multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Disease-modifying Therapies for Multiple Sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

The spectrum of Susac's syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil in the therapy of severe myasthenia gravis

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Factors that influence adherence with disease-modifying therapy in MS.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Obstructive sleep apnea associated with cerebral hypoxemia and death.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1756285609353354

21 January 2018

Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002613

27 October 2018

Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil

1 reference

https://pubmed.ncbi.nlm.nih.gov/21180633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21180633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21180633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term brain atrophy changes in relapsing–remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21180633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil

1 reference

https://pubmed.ncbi.nlm.nih.gov/21180633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1756285609353354

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34409297&oldid=1952083966"